Improving the life of patients through targeted molecular diagnostics and therapies
Compounds administered to more than 1300 patients
CXCR4 compound extensively studied in 150+ scientific papers
Two Phase-III-ready drug candidates
Team of 40 employees with > 50% Ph.D. ratio